Bo-Yu Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bo-Yu Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Hailiang Li
Ningxia Key Laboratory of Craniocerebral Diseases, Yinchuan, China
1 shared publication - Haitao Ran
Department of Ultrasound, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China; Chongqing Key Laboratory of Ultrasound Molecular Imaging and Therapy, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China
1 shared publication - Haiyan Wang
Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China
1 shared publication Hong-Wan Dang
Institute of Clinical Pharmacology and Department of Pharmacy, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China
1 shared publicationJing-Tao Wang
School of Pharmaceutical Science, Southwest University, Chongqing, 40071, P. R. China
1 shared publication- Li Hou
Department of Otolaryngology, Head and Neck Surgery, General Hospital of Ningxia Medical University, Yin Chuan, P. R. China
1 shared publication
Latest Publications
- 11 March 2020
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 8 (9) , 2488-2506
A nanosystem loaded with perfluorohexane and rose bengal coupled upconversion nanoparticles for multimodal imaging and synergetic chemo-photodynamic therapy of cancer
Theranostics is a new trend integrating diagnostic and therapeutic functions in tumour research. Theranostic nanoparticles enabling both tumour imaging and drug delivery are a promising platform for image-guided cancer therapy. Photodynamic therapy (PDT) has great potential in synergy with traditional chemotherapy but faces great challenges due to hypoxia, poor targeting ability and the limited penetration depth of visible light. To solve these problems, we presented a novel nanosystem of FA/UCNPs–RB/HCPT/PFH@lipid (denoted as FURH-PFH-NPs), with a perfluorohexane (PFH) carrying rich oxygen core and a folic acid-modified lipid shell. The shell contains 10-hydroxycamptothecin (HCPT) and self-fluorescing photosensitizer compounds, namely, upconversion nanoparticles and rose bengal (UCNPs–RB). In this study, FURH-PFH-NPs aggregated in SKOV3 cells (in vitro) and the nude xenograft tumour region when combined with folic acid receptors. When triggered by low-intensity focused ultrasound (LIFU), FURH-PFH-NPs released PFH, UCNPs–RB and HCPT. The above procedure was monitored through multimodal imaging, which simultaneously guided the tumour therapy. UCNPs–RB and PFH promoted the PDT effect under LIFU. Through PDT and HCPT, we obtained better therapeutic effects and good biosafety against SKOV3 nude xenograft tumours. FURH-PFH-NPs combined with LIFU and laser irradiation might be a promising strategy for ovarian cancer.
- 11 March 2020
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 8 (9) , 2488-2506
A nanosystem loaded with perfluorohexane and rose bengal coupled upconversion nanoparticles for multimodal imaging and synergetic chemo-photodynamic therapy of cancer
Theranostics is a new trend integrating diagnostic and therapeutic functions in tumour research. Theranostic nanoparticles enabling both tumour imaging and drug delivery are a promising platform for image-guided cancer therapy. Photodynamic therapy (PDT) has great potential in synergy with traditional chemotherapy but faces great challenges due to hypoxia, poor targeting ability and the limited penetration depth of visible light. To solve these problems, we presented a novel nanosystem of FA/UCNPs–RB/HCPT/PFH@lipid (denoted as FURH-PFH-NPs), with a perfluorohexane (PFH) carrying rich oxygen core and a folic acid-modified lipid shell. The shell contains 10-hydroxycamptothecin (HCPT) and self-fluorescing photosensitizer compounds, namely, upconversion nanoparticles and rose bengal (UCNPs–RB). In this study, FURH-PFH-NPs aggregated in SKOV3 cells (in vitro) and the nude xenograft tumour region when combined with folic acid receptors. When triggered by low-intensity focused ultrasound (LIFU), FURH-PFH-NPs released PFH, UCNPs–RB and HCPT. The above procedure was monitored through multimodal imaging, which simultaneously guided the tumour therapy. UCNPs–RB and PFH promoted the PDT effect under LIFU. Through PDT and HCPT, we obtained better therapeutic effects and good biosafety against SKOV3 nude xenograft tumours. FURH-PFH-NPs combined with LIFU and laser irradiation might be a promising strategy for ovarian cancer.